Beta Bionics, Inc. (NASDAQ:BBNX) Assigned Hold Rating by Analysts

Shares of Beta Bionics, Inc. (NASDAQ:BBNX) have been given an average recommendation of "Hold" by three brokerages currently covering the stock, according to Marketbeat.com. All three investment analysts have provided the stock with a hold rating. The average 12-month price target set by these brokers for Beta Bionics is $20.00.

Several research analysts have provided their insights on the stock. LADENBURG THALM/SH SH recently initiated coverage on Beta Bionics, giving it a "neutral" rating with a target price of $20.00. Similarly, Leerink Partners has begun coverage, rating the stock as "outperform" with a target of $28.00. Robert W. Baird also initiated coverage, issuing a "neutral" rating and a $20.00 price objective. Stifel Nicolaus rated Beta Bionics as a "buy" with a target price of $25.00, while Piper Sandler rated the stock as "overweight" with a $26.00 price target.

Insider Activity

In related news, a significant shareholder, Hadley Harbor Aggre Wellington, acquired 1,000,000 shares during a transaction on January 31st. The purchase was made at an average price of $17.00 per share, resulting in a total transaction value of $17,000,000.00. After this acquisition, the insider now holds 3,901,599 shares of the company, approximately worth $66,327,183, which reflects an increase in ownership by 34.46%. This transaction has been disclosed in a filing with the Securities & Exchange Commission, accessible on their website. Additionally, insider Mike Mensinger purchased 33,350 shares on the same day at an average price of $17.00, totaling $566,950.00. Following this purchase, Mensinger now possesses 59,019 shares valued at $1,003,323, representing a substantial increase of 129.92% in ownership.

Beta Bionics Trading Down 1.4%

On Monday, Beta Bionics opened at $20.57. The company has recorded a 52-week low of $20.57 and a high of $24.50.

About Beta Bionics

Beta Bionics, Inc. is a medical device company that focuses on the design, development, and commercialization of solutions for individuals with diabetes who require insulin. Founded by Edward R. Damiano on October 21, 2015, the company is based in Irvine, California.

Investing Insight

If you're considering investing $1,000 in Beta Bionics, it's essential to know that while analysts currently have a "Hold" rating, there are other stocks that top analysts recommend more highly. MarketBeat has identified five stocks that analysts are suggesting as better investment options right now.

This article has been generated for fast and accurate reporting on Beta Bionics and its stock performance. Investors should stay informed about potential opportunities and risks in the market.

Beta, Bionics, Stocks